Physician profile
Lenny Weinstein
NPI 1972772176
$97,224.83
in general payments reported to CMS, 2019-2025
8 companies · $26K in 2025
The $26K reported for 2025 was more than what 96% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,178 · 2020: $48.16 · 2021: $9,966 · 2022: $18K · 2023: $14K · 2024: $26K · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $63K · Food and Beverage: $2,537.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $62,744.75 |
| Food and Beverage | $2,536.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $82,195.34 | 2021-2025 | Dalvance, Avycaz, Teflaro |
| Melinta Therapeutics, LLC | $14,736.13 | 2019-2025 | Rezzayo, Kimyrsa, Orbactiv |
| Janssen Pharmaceuticals, INC | $165.28 | 2021 | |
| Paratek Pharmaceuticals, INC. | $39.97 | 2019 | |
| Merck Sharp & Dohme LLC | $39.34 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.92 | 2024 | Jardiance |
| Chiesi USA, INC. | $13.03 | 2022 | |
| Accelerate Diagnostics INC. | $8.82 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lenny Weinstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.